Supplementary Figure S12 from T-cell Dependency of Tumor Regressions and Complete Responses with RAS(ON) Multi-selective Inhibition in Preclinical Models of Pancreatic Ductal Adenocarcinoma

Key Points

• T cell activation is crucial for effective tumor regression in pancreatic adenocarcinoma.
• RAS(ON) multi-selective inhibition significantly enhances human T cell activation levels.
• The research utilized preclinical models to explore the effects of therapy on tumor responses.
• Findings indicate that targeting RAS(ON) could lead to new therapeutic strategies for pancreatic cancer.